Compare Viatris Inc (VTRS) vs Walmart Stores Inc (WMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Viatris Inc vs Walmart Stores Inc — how do they compare? Viatris Inc trades at $16.3 (market cap $18.69B), while Walmart Stores Inc trades at $115.01 (market cap $901.33B). The key difference: Walmart Stores Inc is far larger — about 48.2× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.95%). Which is the better fit depends on your goals.
| VTRS | WMT | |
|---|---|---|
Market Cap | $18.69B | $901.33B |
Sector | Health | Consumer Staples |
52-Week High | $17.86 | $134.20 |
52-Week Low | $9.49 | $96.05 |
Enterprise Value | $30.80B | $964.78B |
Dividend Yield | 2.95% | 0.87% |
Volume | — | 5,675,288 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Viatris (VTRS) trades at $16.28, down 0.91% on the day, with a bearish technical signal and mixed fundamentals. The company reported a net loss of $3.51 billion in 2025 despite recent quarterly earnings beats, including Q2 2026 EPS of $0.69 versus $0.62 expected. Revenue declined to $14.30 billion in 2025, but operational cash flow remains strong at $2.32 billion. Recent news highlights divestitures and FDA approval for Gwyn Lo, a contraceptive patch.
Outlook is cautious due to persistent losses and high P/E of 236.2, but dividend payments and cost-cutting efforts offer stability. Risks include competitive pressures and debt levels, while analyst consensus leans hold. The stock's value hinges on margin improvement and debt reduction progress.
Walmart (WMT) trades at $112.66, up 0.72% with strong fundamental performance including three consecutive quarterly EPS beats and robust revenue growth to $681B in 2025. The stock shows neutral technical signals with RSI at 62.52, while analyst consensus remains strongly bullish with a $142 price target. Recent developments include AI tool innovations and expanded delivery services positioning the company for continued market leadership.
Walmart presents a compelling investment case with solid fundamentals and analyst support, though valuation multiples appear elevated. Key opportunities include sustained revenue growth and operational efficiency gains, while risks involve competitive pressures from Amazon and potential margin compression. The stock offers 26% upside to consensus targets but requires monitoring of execution against high expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →About Walmart Stores Inc
Walmart Inc. operates discount stores, supercenters, and neighborhood markets. The Company offers merchandise such as apparel, house wares, small appliances, electronics, musical instruments, books, home improvement, shoes, jewelry, toddler, games, household essentials, pets, pharmaceutical products, party supplies, and automotive tools. Walmart serves customers worldwide.
Read more on WMT →
